The Senate Attacks on Pharma Put the Industry in Jeopardy and Consumers at Risk
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Singling out an industry segment won’t solve the underlying problem of healthcare costs.
Advocates of "Medicare for All" like Bernie Sanders underestimate the significant challenges to its implementation while ignoring or dismissing alternative models that achieve the same goal: equitable healthcare access for all.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Marathon Pharmaceuticals is doing some backtracking after the public, the media and now Bernie Sanders objected to the list price of its upcycled corticosteroid for Duchenne muscular dystrophy.
Bernie Sanders appeared on Real Time with Bill Maher to charge that Big Pharma spends more money on marketing and advertising than on research and development. Was he right?
A universal healthcare ballot measure is the latest in a series of cutting edge policy change proposals put in front of Colorado voters. But will it get the support of residents that recreational marijuana did?
The movement to save Lakewood Hospital outside Cleveland seems misguided.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Vermont Sen. Bernie Sanders released details of his "Medicare for all" single-payer healthcare proposal about two hours before the debate, perhaps fueling renewed interest in the Democratic race.
How stressed does Hillary Clinton get when talking about Wall Street or gun control?
Also, a new song from ZDogg, Baidu is in trouble for its medical claims and LifeWatch gets a new FDA clearance.
Theranos founder Elizabeth Holmes has moved to limit its fingerprick blood test vials after being forced on the defensive over its technology claims.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.